Umme Shahera*, Nahida Sultana, Munira Jahan and Shahina Tabassum

Department of Virology, Bangabandhu Sheikh Mujib Medical University, Shahabag, Dhaka, Bangladesh

*Corresponding Author: Umme Shahera, Department of Virology, Bangabandhu Sheikh Mujib Medical University, Shahabag, Dhaka, Bangladesh.

Received: February 21, 2025; Published: March 12, 2025

Abstract

Background: Hepatitis C virus (HCV) is a major cause of chronic liver disease affecting close to 170 million people worldwide. All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. The combination of sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir, a first-in-class NS5A replication complex inhibitor, demonstrate that it is one of the most promising antiviral therapies. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 3. The aim of the study is to evaluate the efficacy and treatment response of Sofosbuvir plus Daclatasvir in HCV patients with genotype 3.

Materials and Methods: A total 24 patients with genotype 3 were included in this study. Patients received tab sofosbuvir 400 mg plus tab daclatasvir 60mg daily for 12 weeks. Outcome was assessed at the end of 4 weeks (RVR), 12 weeks (EVR) and 24 weeks (SVR).

Results: Twenty four patients were recruited in this study. The study population comprised 50% male and 50 % female. Among them 29.2% were between 41-50 ages and 25% were between 31-40 ages. 37.5% patients complaints for loss of appetite. 79.2% were genotype 3b and 20.8% were genotype 3a. All patients received sofosbuvir (400 mg) and daclatasvir (60 mg) for 12 weeks. SVR12 100% were achieved in all of them.

Conclusion: All patients with genotype 3 achieved SVR12 100% after the completion of therapy with sofosbuvir and daclatasvir. The combination of sofosbuvir and an NS5A inhibitor for 12 weeks appears to be a very good further treatment option in patients with whatever the stage of HCV.

Keywords: Hepatitis C Virus; Antiviral Drugs; Sofosbuvir; Daclatasvir

References

1. National Institutes of Health. Consensus Development Conference on Hepatitis C”. Hepatology 36 (2020): S3-S120.
2. Liang TJ., et al. “Pathogenesis, natural history, treatment, and prevention of hepatitis C”. Annals of Internal Medicine 132 (2000): 296-305.
3. Armstrong GL., et al. “The prevalence of hepatitis C virus infection in the United States, 1999 through 2002”. Annals of Internal Medicine 144 (2006): 705-714.
4. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 60. Atlanta, US Dept of Health and Human Services, Centers for Disease Control and Prevention (2005).
5. Yu ML and WL Chuang “Treatment of chronic hepatitis C in Asia: when East meets West”. The Journal of Gastroenterology and Hepatology  24.3 (2009): 336-345.
6. Narahari S., et al. “and geographic distribution of Hepatitis C Virus genotypes in Indian patient cohort”. Infection, Genetics and Evolution 9.4 (2009): 643-645.
7. Manns MP., et al. “Peginterferon alfa-2b plus ribavirin compared with interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial”. Lancet 358.9286 (2005): 958-965.
8. Sofia MJ., et al. “Discovery of a beta-d-2′-deoxy-2′-alfafluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus”. Journal of Medicinal Chemistry 19 (2010): 7202-7218.
9. Gane EJ., et al. “Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C”. The New England Journal of Medicine 1 (2013): 34-44.
10. Sulkowski MS., et al. “Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection”. The New England Journal of Medicine 3 (2014): 211-221.
11. Gao M., et al. “Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect”. Nature7294 (2010): 96-100.
12. Shiffman ML., et al. “Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3”. The New England Journal of Medicine 357 (2007a): 124-134.
13. Fried MW., et al. “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection”. The New England Journal of Medicine 347 (2002): 975-982.
14. Manns MP., et al. “Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial”. Lancet 358 (2001): 958-965.
15. Koyama R., et al. “Necessities of interferon therapy in elderly patients with chronic hepatitis C”. Intervirology 49 (2006): 121-126.
16. Terranova R and Luca S. “Preliminary results of beta-interferon treatment in the elderly”. Controlled Clinical Trials 17 (1996): 123-129.

Citation

Citation: Umme Shahera., et al. “Combination Treatment of Sofosbuvir Plus Daclatasvir for 12 Weeks in HCV Genotype 3-Infected Bangladeshi Patients: Achievment of a Sustained Virological Response".Acta Scientific Gastrointestinal Disorders 8.4 (2025): 16-19.

Copyright

Copyright: © 2025 Umme Shahera., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.